Filing Flows › Insight Molecular Diagnostics (IMDX) › Q2 2026 › vs Q2 2025
Insight Molecular Diagnostics (IMDX) Q2 2026 vs Q2 2025 (year over year)
Insight Molecular Diagnostics's revenue fell $279K (-54%) from $518K in Q2 2025 to $239K in Q2 2026. The biggest changes: Laboratory Services −$276K (-56%); Kitted Products −$3K (-12%).
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Laboratory Services | $218K | $494K | −$276K | -56% |
| Kitted Products | $21K | $24K | −$3K | -12% |
| Revenue | $239K | $518K | −$279K | -54% |
| Other income, net | $142K | $100K | $42K | +42% |
| Net loss | $11.3M | $9.7M | $1.5M | +16% |
| Costs & expenses | $11.6M | $10.4M | $1.3M | +12% |
| Operating costs | $11.6M | $10.4M | $1.3M | +12% |
| Cost of revenue | $82K | $180K | −$98K | -54% |
| Research & development | $4.5M | $3.3M | $1.2M | +37% |
| Sales & marketing | $1.9M | $1.5M | $456K | +31% |
| General & admin | $2.9M | $2.6M | $226K | +9% |
| Other operating costs | $2.3M | $2.8M | −$520K | -19% |
| Operating cash sources | $11.3M | $9.7M | $1.5M | +16% |
| Depreciation & amortization | $665K | $559K | $106K | +19% |
| Share-based compensation | $661K | $504K | $157K | +31% |
| Working capital & other | $666K | $2.5M | −$1.8M | -73% |
| Cash used in operations | $9.3M | $6.2M | $3.1M | +50% |
| Net loss absorbed | $11.3M | $9.7M | $1.5M | +16% |
Questions
How much did Insight Molecular Diagnostics's revenue grow year over year in Q2 2026?
Insight Molecular Diagnostics's revenue fell $279K (-54%) from $518K in Q2 2025 to $239K in Q2 2026.
What drove Insight Molecular Diagnostics's revenue change in Q2 2026?
Laboratory Services −$276K (-56%); Kitted Products −$3K (-12%).